FOCALIN XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FOCALIN XR (FOCALIN XR).
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
| Metabolism | Primarily metabolized via de-esterification to the major inactive metabolite d-ritalinic acid. Minor pathways include hydroxylation and oxidation, mediated by cytochrome P450 enzymes (CYP2D6, CYP3A4 are not major contributors). |
| Excretion | Renal (approximately 90% as unchanged drug and metabolites) |
| Half-life | Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR) |
| Protein binding | Protein binding: ~15%, primarily to albumin |
| Volume of Distribution | Vd: 1.5 L/kg |
| Bioavailability | Oral: 95% (FOCALIN XR) |
| Onset of Action | Oral: 0.5-1 hour for extended-release |
| Duration of Action | 8-12 hours for extended-release formulation |
| Molecular Weight | 269.34 |
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: no adjustment. GFR <30 mL/min: reduce dose by 50%. Hemodialysis: administer after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | Children ≥6 years: initial 5-10 mg orally once daily; increase by 5-10 mg weekly; max 60 mg/day. Weight-based: 0.3-0.5 mg/kg/day. |
| Geriatric use | Start at 5 mg orally once daily; increase slowly; monitor for cardiovascular effects and insomnia. |
| 1st trimester | Dexamethylphenidate crosses the placenta. Use only if potential benefit justifies potential risk to fetus. Limited human data, but animal studies show some teratogenic effects at high doses. |
| 2nd trimester | May cause fetal growth restriction and neonatal withdrawal syndrome. Use only if clearly needed. |
| 3rd trimester | Risk of neonatal withdrawal, including irritability, feeding difficulties, and respiratory distress. Use only if potential benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for FOCALIN XR (FOCALIN XR).
| Placental transfer | Crosses placenta; detectable in fetal circulation. |
| Breastfeeding | Dexamethylphenidate is excreted into breast milk in small amounts. Monitor infant for agitation, insomnia, and poor weight gain. Caution and possible avoidance in breastfeeding mothers. |
■ FDA Black Box Warning
Focalin XR has a high potential for abuse and dependence. Prolonged use may lead to tolerance, psychological dependence, and withdrawal effects. It should be prescribed cautiously, especially in patients with a history of substance abuse.
| Serious Effects |
Hypersensitivity to methylphenidate or any componentUse with MAO inhibitors or within 14 days of discontinuationGlaucomaTics or family history of Tourette syndromeSevere hypertension, angina, or other significant cardiovascular diseaseHyperthyroidism
| Precautions | Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with structural cardiac abnormalities or other serious heart problems., Blood pressure and heart rate increase: monitor for tachycardia and hypertension., Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, new psychotic or manic symptoms, aggression., Seizures: use with caution in patients with seizure disorders., Long-term suppression of growth: monitor height and weight in pediatric patients., Peripheral vasculopathy, including Raynaud's phenomenon., Serotonin syndrome: risk when co-administered with serotonergic drugs. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Insufficient human data; animal studies show increased fetal resorptions and skeletal abnormalities at high doses. Second/third trimesters: Risk of preterm delivery, low birth weight, and neonatal withdrawal (irritability, dysphoria). Use only if benefit justifies risk. |
| Fetal Monitoring | Monitor maternal vital signs (blood pressure, heart rate) and weight; assess for signs of psychosis or dependence. Fetal monitoring via ultrasound for growth restriction if used chronically. |
| Fertility Effects | No human studies; animal studies show no significant effects on fertility. Potential for reversible amenorrhea or menstrual irregularities with chronic use. |
| Avoid high-fat meals around the time of administration, as fat delays Tmax and reduces peak concentration. Avoid alcohol, which can disrupt the extended-release mechanism and lead to a sudden dose dump. Grapefruit juice may inhibit CYP2D6 and potentiate effects; limit or avoid consumption. |
| Clinical Pearls | Focalin XR (dexmethylphenidate extended-release) uses the SODAS (Spheroidal Oral Drug Absorption System) delivery platform providing bimodal release. Avoid concurrent use with MAOIs or within 14 days of discontinuation. Monitor for growth suppression in children, weight loss, and insomnia. May exacerbate tics, anxiety, and psychosis. Not recommended for patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias. Use with caution with pressor agents and anticoagulants. The XR capsule may be opened and contents sprinkled on applesauce for patients with swallowing difficulties; all beads must be swallowed intact without crushing or chewing. |
| Patient Advice | Take exactly as prescribed; do not crush, chew, or divide the capsule. · If you have trouble swallowing, you may open the capsule and sprinkle the beads on a spoonful of applesauce; swallow immediately without chewing. · Avoid taking with high-fat meals as they may delay absorption. · Do not take within 6 hours of bedtime to prevent insomnia. · Avoid alcohol as it can alter the release mechanism and increase side effects. · Notify your doctor if you experience chest pain, shortness of breath, palpitations, or fainting. · Report any new or worsening mental health symptoms such as aggression, hallucinations, or mania. · Monitor weight and height in children; appetite loss is common. · Store at room temperature, away from moisture and heat. · Keep out of reach of children; dependence and abuse are possible. |